# DHM (Dihydromyricetin) Clinical Drug Interaction Reference

**For Healthcare Providers**
**Date:** 2025-11-09

---

## PHARMACOKINETIC PROFILE

| Parameter | Value | Clinical Significance |
|-----------|-------|----------------------|
| **Bioavailability** | Poor (exact % unknown) | Low systemic exposure may reduce interaction risk |
| **Absorption** | Passive diffusion, poorly absorbed | Slow onset, variable absorption |
| **Metabolism** | Extensive first-pass; reduction, dehydroxylation, methylation, glucuronidation, sulfation | Almost complete metabolism within 12 hours |
| **Half-life** | Short (exact value unknown) | Requires multiple daily doses |
| **Protein Binding** | Unknown | Potential for displacement interactions |
| **Excretion** | Unknown (likely renal after metabolism) | Consider in renal impairment |

---

## CYP450 ENZYME INTERACTIONS (In Vitro)

| Enzyme | Effect | IC‚ÇÖ‚ÇÄ / K·µ¢ | Inhibition Type | Clinical Drugs Affected |
|--------|--------|-----------|-----------------|------------------------|
| **CYP3A4** | Inhibitor | IC‚ÇÖ‚ÇÄ 14.75 ŒºM; K·µ¢ 6.06 ŒºM | Non-competitive, time-dependent | Statins, immunosuppressants, CCBs, many others |
| **CYP2E1** | Inhibitor | IC‚ÇÖ‚ÇÄ 25.74 ŒºM; K·µ¢ 9.24 ŒºM | Competitive | Ethanol, acetaminophen, volatile anesthetics |
| **CYP2D6** | Inhibitor | IC‚ÇÖ‚ÇÄ 22.69 ŒºM; K·µ¢ 10.52 ŒºM | Competitive | TCAs, beta-blockers, codeine, tramadol |
| **CYP1A2** | No effect | >100 ŒºM | - | Theophylline, clozapine, caffeine (not affected) |
| **CYP2C9** | No effect | >100 ŒºM | - | Warfarin, NSAIDs, phenytoin (not affected) |
| **CYP2C19** | No effect | >100 ŒºM | - | PPIs, clopidogrel (not affected) |
| **CYP2C8** | No effect | >100 ŒºM | - | Paclitaxel, repaglinide (not affected) |
| **CYP2A6** | No effect | >100 ŒºM | - | Nicotine, coumarin (not affected) |

**Clinical Interpretation:** In vitro inhibition does NOT always translate to clinical significance. Poor DHM bioavailability may limit systemic concentrations needed for CYP inhibition. **Clinical studies needed.**

---

## DRUG TRANSPORTER INTERACTIONS

| Transporter | Effect | IC‚ÇÖ‚ÇÄ | Substrate Drugs |
|-------------|--------|------|-----------------|
| **OATP1B1** | Strong Inhibitor | 1.7-6.4 ŒºM | Statins, methotrexate, rifampin, valsartan |
| **OATP2B1** | Very Strong Inhibitor | 0.3-0.4 ŒºM | Fexofenadine, glyburide, montelukast |
| **P-gp** | Unknown | Not studied | Unknown |
| **BCRP** | Unknown | Not studied | Unknown |

**Clinical Note:** OATP inhibition may increase systemic exposure of substrate drugs ‚Üí enhanced efficacy or toxicity.

---

## DRUG-SPECIFIC INTERACTION TABLE

### CARDIOVASCULAR MEDICATIONS

| Drug | Interaction Mechanism | Evidence Level | Severity | Recommendation | Monitoring |
|------|----------------------|----------------|----------|----------------|-----------|
| **Warfarin** | Additive antiplatelet effects; DHM does NOT inhibit CYP2C9 | Weak (theoretical) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è HIGH | Use with caution; monitor INR closely | INR, bleeding signs |
| **Apixaban/Rivaroxaban** | Possible CYP3A4 interaction (minor pathway) | Weak | ‚ö†Ô∏è‚ö†Ô∏è MODERATE | Inform patient of bleeding risk | Bleeding signs |
| **Aspirin** | Synergistic antiplatelet effects | Moderate (in vitro) | ‚ö†Ô∏è‚ö†Ô∏è MODERATE | May increase bleeding risk | Bleeding time, bruising |
| **Clopidogrel** | No CYP2C19 interaction expected | Weak | ‚ö†Ô∏è LOW | Likely safe; monitor bleeding | Bleeding signs |
| **Atorvastatin** | CYP3A4 inhibition (theoretical) | Weak | ‚ö†Ô∏è‚ö†Ô∏è MODERATE | Monitor for myopathy | CK, LFTs, muscle pain |
| **Simvastatin** | CYP3A4 inhibition (theoretical) | Weak | ‚ö†Ô∏è‚ö†Ô∏è MODERATE | Consider pravastatin instead | CK, LFTs |
| **Pravastatin** | No CYP interaction | None | ‚úÖ LOW | Preferred statin if concerned | Routine monitoring |
| **Amlodipine** | CYP3A4 substrate | Weak | ‚ö†Ô∏è LOW | Monitor BP; likely minor | BP, edema |
| **Diltiazem** | CYP3A4 substrate | Weak | ‚ö†Ô∏è LOW-MODERATE | Monitor HR, BP | HR, BP, AV conduction |
| **Metoprolol** | CYP2D6 substrate | Weak | ‚ö†Ô∏è LOW | Monitor HR, BP | HR, BP |

---

### ENDOCRINE MEDICATIONS

| Drug | Interaction Mechanism | Evidence Level | Severity | Recommendation | Monitoring |
|------|----------------------|----------------|----------|----------------|-----------|
| **Metformin** | Synergistic GLP-1 enhancement, improved insulin sensitivity | Moderate (animal + limited human) | ‚ö†Ô∏è‚ö†Ô∏è MODERATE | Monitor glucose closely; may enhance effect | FBG, HbA1c, hypoglycemia symptoms |
| **Insulin** | Additive glucose-lowering | Weak (theoretical) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è HIGH | **Risk of hypoglycemia**; reduce insulin dose | BG monitoring q2-4h initially |
| **Sulfonylureas** | Additive glucose-lowering | Weak (theoretical) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è HIGH | **Risk of hypoglycemia** | BG monitoring, hypoglycemia symptoms |
| **GLP-1 agonists** | Possible additive effects | Weak (theoretical) | ‚ö†Ô∏è MODERATE | Monitor glucose | BG, GI symptoms |
| **Levothyroxine** | Unknown; possible absorption interaction | None | ‚ùì UNKNOWN | Separate by ‚â•4 hours | TSH at 6-8 weeks |

---

### CNS MEDICATIONS

| Drug | Interaction Mechanism | Evidence Level | Severity | Recommendation | Monitoring |
|------|----------------------|----------------|----------|----------------|-----------|
| **Diazepam** | GABA-A receptor (BZ site) modulation | Moderate (animal flumazenil antagonism) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è HIGH | **May alter benzodiazepine effects**; avoid or adjust dose | Sedation level, withdrawal symptoms |
| **Lorazepam** | GABA-A receptor interaction | Moderate | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è HIGH | Same as diazepam | Sedation, cognition |
| **Alprazolam** | GABA-A + CYP3A4 substrate | Moderate | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è HIGH | Dual interaction risk | Sedation, respiratory rate |
| **Zolpidem** | GABA-A receptor agonist | Moderate | ‚ö†Ô∏è‚ö†Ô∏è MODERATE | May potentiate sedation | Morning drowsiness, falls risk |
| **SSRIs** | Unknown mechanism | None | ‚ùì UNKNOWN | No data; use caution | Serotonin syndrome unlikely |
| **MAOIs** | Unknown mechanism | None | ‚ùì UNKNOWN | **Avoid** until safety data available | Multiple symptoms |
| **TCAs** | CYP2D6 substrate | Weak | ‚ö†Ô∏è LOW-MODERATE | Monitor for TCA toxicity | ECG, anticholinergic effects |
| **Codeine** | CYP2D6 (prodrug activation) | Weak | ‚ö†Ô∏è LOW | May reduce analgesic effect | Pain control |
| **Tramadol** | CYP2D6 substrate | Weak | ‚ö†Ô∏è LOW | May alter efficacy | Pain control |

---

### IMMUNOSUPPRESSANTS

| Drug | Interaction Mechanism | Evidence Level | Severity | Recommendation | Monitoring |
|------|----------------------|----------------|----------|----------------|-----------|
| **Tacrolimus** | CYP3A4 substrate (major) | Weak (theoretical) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **DO NOT USE** without transplant team approval | Trough levels, renal function |
| **Cyclosporine** | CYP3A4 substrate (major) | Weak (theoretical) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **DO NOT USE** without transplant team approval | Trough levels, BP, renal function |
| **Sirolimus** | CYP3A4 substrate | Weak (theoretical) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **DO NOT USE** without approval | Trough levels |
| **Mycophenolate** | No known interaction | None | ‚úÖ LOW | Likely safe | Routine monitoring |
| **Prednisone** | Unknown | None | ‚ö†Ô∏è LOW | Likely safe | Routine monitoring |

**‚ö†Ô∏è CRITICAL:** Transplant patients should NOT use DHM without explicit approval from transplant team. Risk of altered immunosuppressant levels ‚Üí rejection or toxicity.

---

### ONCOLOGY MEDICATIONS

| Drug | Interaction Mechanism | Evidence Level | Severity | Recommendation | Monitoring |
|------|----------------------|----------------|----------|----------------|-----------|
| **Cisplatin** | DHM protects normal cells; may enhance cancer cell death | Strong (in vitro + animal) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **Oncologist approval required**; may alter dosing | Toxicity, response |
| **Paclitaxel** | DHM reverses resistance | Strong (in vitro) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **Oncologist approval required** | Response, toxicity |
| **Doxorubicin** | DHM reverses resistance | Strong (in vitro) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **Oncologist approval required** | Cardiac toxicity, response |
| **5-Fluorouracil** | DHM reverses MDR | Moderate (in vitro) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **Oncologist approval required** | Response, toxicity |
| **Erlotinib** | Synergistic apoptosis | Moderate (in vitro) | ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è **CRITICAL** | **Oncologist approval required** | EGFR mutation, response |

**‚ö†Ô∏è CRITICAL:** DHM significantly alters chemotherapy pharmacodynamics. **MANDATORY oncologist consultation** before any use.

---

### ANTIMICROBIALS

| Drug | Interaction Mechanism | Evidence Level | Severity | Recommendation | Monitoring |
|------|----------------------|----------------|----------|----------------|-----------|
| **Fluconazole** | No significant PK interaction despite CYP3A4 inhibition | Moderate (rat PK study) | ‚úÖ LOW | Safe co-administration | Routine |
| **Gentamicin** | DHM is nephroprotective | Moderate (animal) | ‚úÖ BENEFICIAL | May reduce nephrotoxicity | SCr, BUN |
| **Rifampin** | CYP inducer (may reduce DHM levels) | Weak | ‚ö†Ô∏è LOW | Unlikely clinical issue | None |

---

### ANESTHETICS

| Drug | Interaction Mechanism | Evidence Level | Severity | Recommendation | Monitoring |
|------|----------------------|----------------|----------|----------------|-----------|
| **Volatile anesthetics** | CYP2E1 metabolism | Weak | ‚ö†Ô∏è LOW | Likely minimal impact | Routine anesthesia monitoring |
| **Propofol** | GABA-A receptor | Weak (theoretical) | ‚ö†Ô∏è MODERATE | May potentiate sedation | Depth of anesthesia |
| **Midazolam** | GABA-A + CYP3A4 | Moderate | ‚ö†Ô∏è‚ö†Ô∏è MODERATE | Possible dual interaction | Sedation depth, recovery time |

**Perioperative Guideline:** **STOP DHM 14 days before elective surgery** due to antiplatelet effects.

---

## CONTRAINDICATIONS TABLE

| Contraindication | Absolute/Relative | Rationale | Evidence |
|------------------|-------------------|-----------|----------|
| **Pregnancy** | Absolute | No safety data; unknown fetal effects | None (lack of data) |
| **Lactation** | Absolute | May pass into breast milk; infant effects unknown | None (lack of data) |
| **Pediatrics (<18 years)** | Absolute | No safety or PK data in children | None (lack of data) |
| **Phenylketonuria (PKU)** | Absolute | May contain phenylalanine | Manufacturer warnings |
| **Active bleeding** | Absolute | Antiplatelet effects | Moderate (animal) |
| **Hemophilia/bleeding disorders** | Absolute | Antiplatelet effects | Theoretical |
| **14 days pre-surgery** | Absolute | Bleeding risk | Theoretical |
| **Organ transplant** | Relative (require approval) | CYP3A4 interaction with immunosuppressants | Weak (theoretical) |
| **Severe hepatic impairment** | Relative (caution) | Altered metabolism | None |
| **Severe renal impairment** | Relative (caution) | Unknown excretion pathway | None |

---

## CLINICAL TRIAL SAFETY DATA

| Study | Population | Dose | Duration | Adverse Events |
|-------|-----------|------|----------|----------------|
| **NAFLD Trial** | 60 Chinese adults with NAFLD | 150 mg BID | 3 months | **ZERO adverse events** |
| **Insulin Sensitivity Study** | Type 2 diabetics | Up to 600 mg/day | Short-term | No serious adverse events |
| **Dose Escalation (NCT05623501)** | Alcohol-associated liver disease | Variable (Phase I) | Ongoing | Ongoing |
| **Glycemic Control (NCT03606694)** | Type 2 diabetes | Variable | Ongoing | Ongoing |

**Overall Clinical Safety:** Minimal adverse events in all human trials to date. Most common: mild GI upset (rare).

---

## MECHANISM-BASED ADVERSE EFFECTS

| Mechanism | Potential Adverse Effect | Monitoring | Mitigation |
|-----------|-------------------------|------------|------------|
| **Antiplatelet activity** | Bleeding, bruising | CBC, PT/INR if on anticoagulants | Avoid with anticoagulants; stop before surgery |
| **CYP3A4 inhibition** | Increased levels of CYP3A4 substrates | Drug levels (tacrolimus, cyclosporine, etc.) | Dose adjustment of substrate drugs |
| **GABA-A modulation** | Altered sedation, anxiety | Sedation scales, anxiety symptoms | Avoid with benzodiazepines |
| **Glucose-lowering** | Hypoglycemia | Blood glucose | Reduce diabetes medication doses |
| **OATP inhibition** | Increased statin/drug levels | CK, LFTs (statins) | Use non-OATP substrate alternatives |

---

## DOSING RECOMMENDATIONS

| Indication | Dose | Frequency | Duration | Evidence |
|------------|------|-----------|----------|----------|
| **Hangover prevention** | 300-600 mg | 30 min before alcohol | Single dose | Multiple studies |
| **Hangover treatment** | 100-200 mg | After drinking | Single dose | Clinical experience |
| **NAFLD/metabolic syndrome** | 150 mg | BID | 3-6 months | 1 RCT |
| **Diabetes** | 150-600 mg | Daily | Ongoing | Under investigation |
| **General supplementation** | 300-1000 mg | Daily | Variable | Clinical experience |

**Maximum Documented Safe Dose:** 1200 mg/day for several weeks (no serious AEs)
**Estimated Toxicity Threshold:** >16 g/day (based on animal LD‚ÇÖ‚ÇÄ conversion)

---

## HEPATOTOXICITY ASSESSMENT

| Parameter | Finding | Source |
|-----------|---------|--------|
| **LiverTox Classification** | NOT associated with liver injury | NIH LiverTox Database (NBK594407) |
| **Serum enzyme elevations** | NOT reported in clinical trials | Multiple studies |
| **Clinically apparent liver injury** | NOT reported | Literature review |
| **DILI risk** | Minimal to none | Clinical trial data |
| **Hepatoprotective effects** | Strong evidence (NAFLD, alcohol, drug-induced injury) | Multiple animal + human studies |

**Clinical Conclusion:** DHM is hepatoprotective, not hepatotoxic. Safe in liver disease (unless decompensated cirrhosis).

---

## NEPHROTOXICITY ASSESSMENT

| Parameter | Finding | Source |
|-----------|---------|--------|
| **Renal injury reports** | NONE | Literature review |
| **Nephroprotective effects** | Strong (cisplatin, gentamicin, diabetic nephropathy) | Multiple animal studies |
| **BUN/Creatinine elevation** | NOT reported | Clinical trials |
| **Renal safety in CKD** | Unknown (no human data) | - |

**Clinical Conclusion:** DHM appears renoprotective. Likely safe in kidney disease, but no data in ESRD/dialysis.

---

## LABORATORY MONITORING RECOMMENDATIONS

| If Patient Taking... | Baseline Labs | Monitoring Labs | Frequency |
|---------------------|---------------|-----------------|-----------|
| **Warfarin + DHM** | INR, PT, CBC | INR, signs of bleeding | Weekly √ó 4 weeks, then monthly |
| **Diabetes meds + DHM** | HbA1c, FBG | Blood glucose | Daily (home), HbA1c q3 months |
| **Tacrolimus/Cyclosporine + DHM** | Trough level, SCr, BUN | Trough level, renal function | 3-7 days after starting DHM, then weekly |
| **Statins + DHM** | CK, ALT, AST | CK, LFTs, muscle symptoms | 4-6 weeks, then q3-6 months |
| **No interacting drugs** | None required | None required | - |

---

## SPECIAL POPULATIONS

| Population | Recommendation | Rationale |
|------------|---------------|-----------|
| **Pregnancy** | **AVOID** | No safety data; unknown teratogenicity |
| **Lactation** | **AVOID** | May pass into breast milk; unknown infant effects |
| **Children (<18)** | **AVOID** | No pediatric PK or safety data |
| **Elderly (>65)** | Use with caution | No geriatric-specific data; polypharmacy risk |
| **Hepatic impairment (mild-moderate)** | Likely safe | DHM is hepatoprotective |
| **Hepatic impairment (severe/decompensated)** | Use with caution | Altered metabolism; no data |
| **Renal impairment (mild-moderate)** | Likely safe | DHM is renoprotective |
| **Renal impairment (severe/ESRD)** | Unknown | Unknown excretion pathway |
| **Transplant recipients** | **AVOID** unless team approves | CYP3A4 interaction with immunosuppressants |

---

## PATIENT COUNSELING POINTS

1. ‚úÖ **Inform all healthcare providers** you're taking DHM (including dentists, surgeons)
2. ‚ö†Ô∏è **Stop 14 days before** any scheduled surgery
3. ‚ö†Ô∏è **Report unusual bleeding** or bruising immediately
4. ‚ö†Ô∏è **Monitor blood glucose** closely if diabetic (may reduce medication needs)
5. ‚ö†Ô∏è **Do NOT adjust** prescription medications without consulting physician
6. ‚ö†Ô∏è **Avoid if pregnant** or breastfeeding
7. ‚ö†Ô∏è **Not for children** under 18
8. ‚ÑπÔ∏è **Take with food** to improve absorption and reduce GI upset
9. ‚ÑπÔ∏è **Separate from thyroid medication** by at least 4 hours
10. ‚òéÔ∏è **Call your doctor if** you experience concerning symptoms

---

## DECISION ALGORITHM FOR CLINICIANS

```
Patient requests DHM supplementation
          ‚Üì
Pregnant/breastfeeding/pediatric?
  YES ‚Üí CONTRAINDICATED ‚ùå
  NO ‚Üí Continue
          ‚Üì
Organ transplant recipient?
  YES ‚Üí TRANSPLANT TEAM CONSULTATION REQUIRED ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è
  NO ‚Üí Continue
          ‚Üì
On anticoagulants OR surgery within 14 days?
  YES ‚Üí HIGH RISK - Discuss alternatives or monitor closely ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è
  NO ‚Üí Continue
          ‚Üì
On chemotherapy?
  YES ‚Üí ONCOLOGIST CONSULTATION REQUIRED ‚ö†Ô∏è‚ö†Ô∏è‚ö†Ô∏è
  NO ‚Üí Continue
          ‚Üì
On diabetes meds, benzodiazepines, or immunosuppressants?
  YES ‚Üí MODERATE RISK - Close monitoring required ‚ö†Ô∏è‚ö†Ô∏è
  NO ‚Üí Continue
          ‚Üì
On CYP3A4 substrates (statins, CCBs, etc.)?
  YES ‚Üí LOW-MODERATE RISK - Monitor for drug effects ‚ö†Ô∏è
  NO ‚Üí Continue
          ‚Üì
Otherwise healthy, no medications?
  YES ‚Üí LOW RISK - Likely safe ‚úÖ
          ‚Üì
     APPROVE with standard counseling
```

---

## REGULATORY STATUS

| Jurisdiction | Classification | Approved Uses | Notes |
|--------------|---------------|---------------|-------|
| **United States (FDA)** | Dietary Supplement | None (not approved drug) | Not regulated for safety/efficacy |
| **European Union** | Novel Food/Supplement | None | Limited regulation |
| **China** | Traditional Medicine/Supplement | Hangover, liver support | From Ampelopsis grossedentata (vine tea) |

**Clinical Implication:** DHM is NOT FDA-approved for any medical condition. Off-label use as dietary supplement.

---

## REPORTING ADVERSE EVENTS

**Healthcare providers should report suspected DHM adverse events to:**
- **FDA MedWatch:** 1-800-FDA-1088 or www.fda.gov/medwatch
- **Manufacturer** (if known)
- **PubMed case reports** (for medical literature)

**Important:** Due to limited post-market surveillance, all serious AEs should be reported.

---

## EVIDENCE QUALITY GRADING

| Drug Interaction | Evidence Level | Study Type | Clinical Confidence |
|------------------|---------------|------------|---------------------|
| CYP450 inhibition | **Moderate** | In vitro | Low-Moderate (no human PK studies) |
| Antiplatelet effects | **Moderate** | Animal | Low (no human hemostasis studies) |
| GABA-A modulation | **Moderate** | In vitro + animal | Low-Moderate (flumazenil reversal) |
| Metformin synergy | **Moderate** | Animal + limited human | Moderate |
| Chemotherapy interactions | **Strong** | In vitro + animal | Low (no human oncology studies) |
| Fluconazole interaction | **Moderate** | Rat PK study | Moderate (negative result) |
| Hepatoprotection | **Strong** | Animal + human trials | Strong |

**Overall Confidence:** Most interactions are theoretical or based on animal data. **Clinical studies urgently needed.**

---

## REFERENCES - KEY CITATIONS

1. **PMID 28614988** - CYP450 inhibition (in vitro)
2. **PMID 39344282** - OATP/CYP interactions (conflicting CYP data)
3. **PMID 33711433** - Anti-thrombotic effects (platelets + fibrin)
4. **PMID 22219299** - GABA-A modulation, anti-alcohol effects
5. **PMC6830359** - Insulin sensitivity, diabetes
6. **PMID 28436480** - Chemotherapy resistance reversal
7. **NBK594407** - LiverTox (hepatotoxicity assessment)
8. **NCT03606694** - Ongoing diabetes clinical trial
9. **NCT05623501** - Ongoing dose-escalation trial (ALD)

---

## CLINICAL BOTTOM LINE

‚úÖ **DHM appears safe** in healthy adults without drug interactions
‚ö†Ô∏è **High caution** with anticoagulants, diabetes meds, benzodiazepines, transplant drugs, chemotherapy
üö´ **Contraindicated** in pregnancy, lactation, pediatrics, active bleeding
‚ùì **Unknown safety** with many common medications (SSRIs, thyroid, many others)
üìä **Evidence gaps** - Most data from animals/in vitro; human drug interaction studies needed

**Recommendation:** Use shared decision-making. If patient insists on DHM, ensure close monitoring and clear documentation of risks/benefits discussion.

---

**Document Version:** 1.0
**Last Updated:** 2025-11-09
**Next Review:** Update when new clinical trials published (NCT03606694, NCT05623501)
